<DOC>
	<DOC>NCT00418626</DOC>
	<brief_summary>This study will be a formal assessment of the impact of hepatic function impairment on the pharmacokinetics of nilotinib</brief_summary>
	<brief_title>Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function</brief_title>
	<detailed_description />
	<criteria>1. Healthy adult male (18 70 yrs) 2. Body weight must be â‰¥ 50 kg and &lt; 120 kg, with a body mass index (BMI) &gt;18 but &lt; 35. 3. Laboratory parameters values within the normal range 1. Contraindication or hypersensitivity to receiving nilotinib 2. Smokers or those who use of tobacco products or products containing nicotine 3. A past medical history of clinically significant Electrocardiogram abnormalities or a history/family history of long QTinterval syndrome. 4. History of fainting spells. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>nilotinib</keyword>
	<keyword>hepatic impairment</keyword>
	<keyword>Child-Pugh scale</keyword>
	<keyword>PK</keyword>
	<keyword>healthy, subject(s)</keyword>
	<keyword>Subjects with impaired hepatic function and healthy subjects</keyword>
</DOC>